As of the close on 5 December 2025, Medtronic plc (NYSE: MDT) stock trades around $101.36–$101.39 per share, giving the medical device giant a market capitalization of roughly $130 billion, a P/E ratio near 27.4, and a dividend yield of about 2.8%. [1]
In the first week of December, Medtronic has delivered a flurry of stock‑moving news: a new FDA clearance for its Hugo™ robotic-assisted surgery system, a U.S. launch of its next‑gen MiniMed™ 780G insulin pump with Abbott’s Instinct™ sensor, a fresh quarterly dividend declaration, and ongoing progress toward the spin‑off of its Diabetes business. At the same time, analysts have tweaked ratings and large institutions have shifted their positions.
Here’s a detailed, investor‑focused look at the latest Medtronic stock news, forecasts and analysis as of 6 December 2025.
Medtronic Stock Snapshot on 6 December 2025
- Share price: ~$101.4 at the 5 December close, after-hours trading broadly flat. [2]
- 52‑week range: $79.29 – $106.33. [3]
- Market cap: About $129.9–$130.0 billion. [4]
- Valuation: Trailing P/E ~27.3 and PEG ratio ~2.7, implying investors are paying a premium for Medtronic’s improving growth profile. [5]
- Balance sheet: Debt‑to‑equity of 0.57, current ratio 2.42 and quick ratio 1.80, signalling a solid liquidity profile and moderate leverage. [6]
After several years of underperformance, Medtronic shares are up more than 30% year to date, supported by better growth, restructuring, and a pipeline that is finally converting into commercial products. [7]
Fresh 6 December 2025 Headlines: Ratings Shift and Big Money Moves
Wall Street Zen Downgrade to “Hold”
On 6 December 2025, MarketBeat reported that Wall Street Zen downgraded Medtronic from “Buy” to “Hold.” The move followed Medtronic’s strong fiscal Q2 2026 results but reflects a view that near‑term upside may be more limited after this year’s rally. [8]
Even with this downgrade, the overall analyst stance remains constructive:
- MarketBeat counts 26 analysts covering MDT with a “Moderate Buy” consensus.
- The average 12‑month price target is $110.44, implying about 9% upside from the recent ~$101.4 share price, with targets ranging from $100 to $120. [9]
StockAnalysis data shows a similar picture:
- 16 analysts with a consensus “Buy”,
- Average price target of $108.63, with a range of $98 to $118, implying ~7% upside. [10]
Institutional Investors: Amundi Buys, Cresset Trims, Tema ETFs Adds
Also today, multiple 13F‑driven headlines highlighted meaningful institutional flows into Medtronic: [11]
- Amundi increased its stake by 18.8% in Q2, buying 803,584 shares and bringing its holdings to 5.08 million shares (about 0.40% of the company), valued near $448 million. [12]
- Tema ETFs disclosed a new position of 20,568 MDT shares in a recent filing, a relatively small but noteworthy vote of confidence from an active ETF manager. [13]
- Cresset Asset Management cut its stake by 8.5%, selling 16,618 shares and ending the quarter with 178,873 shares worth roughly $15.7 million. [14]
MarketBeat notes that, overall, around 82% of Medtronic’s shares are owned by institutions, underscoring its status as an institutional core holding. [15]
Dividend Update: 48 Years of Increases and Counting
On 4 December 2025, Medtronic’s board approved a cash dividend of $0.71 per ordinary share for the third quarter of fiscal 2026. [16]
Key details for income investors:
- Quarterly dividend: $0.71 per share. [17]
- Annualized dividend: $2.84 per share (roughly a 2.8% yield at recent prices). [18]
- Record date: 26 December 2025.
- Payment date: 16 January 2026. [19]
- Dividend track record: Medtronic has now raised its dividend for 48 consecutive years, placing it in the S&P 500 Dividend Aristocrats index and putting it two years away from coveted “Dividend King” status (50+ years of increases). [20]
Several recent articles from income‑focused outlets highlight Medtronic as a top dividend stock heading into 2026, thanks to its combination of yield, consistency and improving growth. [21]
New Product Catalysts: Robotics, Diabetes Tech and Hypertension Treatment
1. Hugo™ Robotic-Assisted Surgery System Wins FDA Clearance
On 3 December 2025, Medtronic announced that the Hugo™ robotic‑assisted surgery (RAS) system received FDA clearance for minimally invasive urologic procedures, including prostatectomy, nephrectomy and cystectomy. [22]
Key points:
- Hugo is now cleared in the U.S. for a urology indication that represents around 230,000 surgeries per year. [23]
- The decision was supported by the EXPAND URO investigational device exemption (IDE) study, described as the largest U.S. multi‑port robotic urology trial, which met primary safety and effectiveness endpoints. [24]
- Outside the U.S., Hugo has already been used in tens of thousands of procedures across more than 30 countries, giving Medtronic real‑world data and training experience as it rolls out in the U.S. [25]
- Medtronic plans a “purposeful” U.S. launch, with future plans to seek indications for general and gynecologic surgery, which would vastly expand the addressable market and deepen competition with Intuitive Surgical. [26]
For investors, Hugo is a long‑term growth driver: the global robotic surgery market is still underpenetrated, and Medtronic believes fewer than 5% of eligible procedures are currently performed robotically. [27]
2. U.S. Launch of MiniMed™ 780G With Abbott’s Instinct™ Sensor
On 2 December 2025, Medtronic began its broad U.S. commercial launch of the MiniMed™ 780G insulin pump system integrated with Abbott’s Instinct™ continuous glucose monitoring (CGM) sensor. [28]
Highlights:
- The Instinct sensor uses Abbott’s most advanced CGM technology, featuring a very small, discreet sensor with up to 15 days of wear. [29]
- When paired with the MiniMed 780G, the system automatically adjusts insulin every five minutes using real‑time glucose data, aiming to reduce highs and lows and lighten daily diabetes management. [30]
- The launch expands Medtronic’s CGM ecosystem alongside its Simplera Sync™ and Guardian™ 4 sensors, giving patients more flexible options. [31]
Zacks notes that this rollout could support Medtronic’s Diabetes segment growth and potentially lift MDT stock over time, despite intense competition from Dexcom and Abbott in CGM and from other pump makers. [32]
3. National Coverage Determination for Symplicity Spyral™ Renal Denervation
On 28 October 2025, the Centers for Medicare & Medicaid Services (CMS) finalized a National Coverage Determination (NCD) for renal denervation, explicitly covering Medtronic’s Symplicity Spyral™ renal denervation (RDN) system for certain Medicare patients with uncontrolled hypertension. [33]
This is a major reimbursement milestone:
- The NCD allows appropriate Medicare patients to access Symplicity Spyral when lifestyle changes and medications have not adequately controlled blood pressure. [34]
- Cardiologists and CMS observers expect the decision to accelerate adoption of RDN as an adjunctive therapy, filling a gap for difficult‑to‑treat hypertension. [35]
- Medtronic’s management has called RDN one of the company’s “most exciting growth drivers”, noting the large population of hypertension patients who may benefit. [36]
In the fiscal Q2 release, Medtronic highlighted the combination of RDN, its pulsed field ablation (PFA) portfolio, Hugo robotics and new therapies like Altaviva™ for urge urinary incontinence as a set of enterprise growth drivers expected to accelerate revenue growth in the second half of FY26 and beyond. [37]
Earnings Momentum: Strong Fiscal Q2 2026 Results and Raised Guidance
Medtronic reported fiscal Q2 2026 (quarter ended 24 October 2025) results on 18 November 2025, beating Wall Street expectations and raising its full‑year outlook. [38]
Headline numbers
- Revenue:$8.96–$9.0 billion, up 6.6% year over year as reported and 5.5% organic, about 75 basis points above the guidance midpoint. [39]
- Non‑GAAP diluted EPS:$1.36, up 8% year over year and ahead of consensus ($1.31). [40]
- GAAP EPS: $1.07, also up 8%. [41]
- Operating margins: Non‑GAAP operating margin around 24.1%, up 6% in absolute profit despite modest margin pressure from tariffs and investment. [42]
Segment performance
- Cardiovascular Portfolio: Revenue $3.44 billion, up 10.8% reported / 9.3% organic, the strongest cardiovascular growth in over a decade (ex‑pandemic). [43]
- Cardiac Ablation Solutions grew 71% overall, including 128% growth in the U.S., driven by its pulsed field ablation (PFA) franchise (Affera mapping system and Sphere‑9 catheter). [44]
- Neuroscience Portfolio:$2.56 billion in revenue, up 4.5% reported / 3.9% organic, with strength in Neuromodulation and Cranial & Spinal Technologies. [45]
- Medical Surgical Portfolio:$2.17 billion, up 2.1% reported / 1.3% organic, modest but positive growth. [46]
- Diabetes:$757 million, up 10.3% reported / 7.1% organic, reflecting strong adoption of MiniMed 780G and newer CGM systems — momentum that should transfer to the planned MiniMed spin‑off. [47]
Updated FY26 Guidance
Medtronic raised its fiscal 2026 guidance: [48]
- Organic revenue growth: Now ~5.5%, up from prior guidance of 5.0%.
- Non‑GAAP diluted EPS: New range $5.62–$5.66, slightly above the prior $5.60–$5.66.
- Management noted this outlook includes an estimated tariff headwind of around $185 million; excluding this, EPS growth would be about 4.5%. [49]
Analysts widely saw this as evidence that Medtronic is entering a new growth phase, using efficiency gains and pipeline launches to offset tariff‑related costs. [50]
Diabetes Spin-Off: MiniMed as a Separate Company by 2026
One of the biggest strategic shifts for Medtronic is its plan to separate its Diabetes business into a new, standalone company.
What Medtronic Announced
On 21 May 2025, Medtronic announced its intent to separate the Diabetes business into a new public company (currently referred to as “New Diabetes Company,” later named MiniMed). [51]
Key points:
- The diabetes division generated roughly $2.8 billion in FY 2025 revenue, with 10.7% year‑over‑year growth and strong momentum in insulin pumps and CGM. [52]
- Medtronic plans to complete the separation within about 18 months of the announcement (i.e., by late 2026), most likely via an IPO followed by a split‑off. [53]
- The spin‑off is intended to:
Recent commentary emphasises that the separation could act as a “shot in the arm” for both entities by clarifying strategies, aligning incentives and enabling more agile investment in digital diabetes tools. [56]
Analyst Forecasts and Valuation: Moderate Upside, Improving Quality
Street Price Targets and Ratings
Across multiple platforms, Medtronic sits in a Buy / Moderate Buy zone:
- MarketBeat:
- Consensus rating: Moderate Buy based on 26 analysts (12 Hold, 13 Buy, 1 Strong Buy).
- Average price target:$110.44, about 8.9% upside from ~$101.4, with a $100–$120 range. [57]
- StockAnalysis:
- Analyst consensus: Buy.
- Average price target:$108.63 (+7.2% vs. current price), with a $98–$118 range. [58]
Recent target hikes underscore growing optimism:
- RBC Capital: Target raised to $118 (Buy). [59]
- Morgan Stanley: Target lifted to $117 (Buy/Overweight). [60]
- Barclays: Target increased to $111 (Overweight). [61]
At the same time, some analysts like Wall Street Zen now rate MDT a Hold, arguing the shares may already discount a portion of the near‑term growth and that tariff headwinds and spin‑off execution risk justify caution. [62]
Zacks: Value Tilt and Rank Upgrade
A recent Zacks / Nasdaq analysis comparing Medtronic (MDT) with EssilorLuxottica (ESLOY) highlights Medtronic’s relatively attractive valuation: [63]
- Forward P/E: ~18.1 for MDT vs. ~43.0 for ESLOY.
- PEG ratio: 2.69 for MDT vs. 4.29 for ESLOY.
- Price‑to‑book (P/B): ~2.68 for MDT vs. ~3.77 for ESLOY.
On this basis, Zacks assigns Medtronic a Value grade of “B” and a Zacks Rank #2 (Buy), signalling improving earnings revisions and reasonable valuation for a high‑quality medtech name. [64]
Earnings and Revenue Forecasts
StockAnalysis consensus forecasts call for: [65]
- Revenue this year: ~$36.4 billion, up about 8.6% from $33.5 billion.
- Revenue next year: ~$38.6 billion, implying ~5.8% growth.
- EPS this year: ~$5.70, up almost 58% vs. a depressed prior‑year figure (influenced by one‑offs).
- EPS next year: ~$6.18, another 8.4% increase.
Overall, analysts expect mid‑single‑digit revenue growth paired with high‑single‑digit EPS growth, supported by margin initiatives and high‑value product launches but tempered by tariffs and spin‑off complexity. [66]
Key Bullish Drivers for Medtronic Stock
From the latest news and forecasts, the bullish thesis for MDT today typically rests on several pillars:
- Re‑accelerating Growth After a Five‑Year Slump
Independent analysis notes that Medtronic’s stock has surged over 30% year‑to‑date, as investors increasingly believe the company has entered a new growth cycle following five years of sluggish performance. The turnaround is anchored in double‑digit Cardiovascular growth, strong Q2 results and upgraded guidance. [67] - Robotic Surgery Upside (Hugo RAS)
Hugo’s U.S. clearance gives Medtronic a credible foothold in the multi‑billion‑dollar robotic surgery market, which remains under‑penetrated and dominated by Intuitive Surgical. Even modest share capture can materially move the needle over time, particularly with future general‑surgery indications. [68] - New Hypertension Therapy Revenue (Symplicity Spyral RDN)
The CMS NCD opens reimbursement for renal denervation in Medicare patients with uncontrolled hypertension, a large and underserved population, positioning Symplicity as a high‑growth franchise within Cardiovascular. [69] - Diabetes Spin-Off Unlocking Value and Focus
Spinning off the Diabetes unit into MiniMed could:- Unlock the value of a fast‑growing but lower‑margin, consumer‑oriented business, and
- Improve the margin profile and strategic focus of the remaining Medtronic. [70]
- Dividend Aristocrat With Room to Grow
With 48 consecutive years of dividend increases, a 2.8% yield, and low‑double‑digit payout growth historically, Medtronic appeals strongly to income and total‑return investors who want both yield and growth. [71]
Key Risks and Bearish Considerations
Investors should balance these positives against meaningful risks:
- Tariff Headwinds and Cost Inflation
Commentary from Barron’s and others suggests new tariffs could raise Medtronic’s cost of goods by up to roughly $950 million in FY26 before mitigation, leaving a net $200–$350 million cost headwind even after supply‑chain adjustments. This is a major reason full‑year EPS growth expectations are muted relative to historic levels. [72] - Execution Risk Around the Diabetes Spin-Off
The MiniMed separation involves regulatory approvals, capital markets execution and complex operational untangling. Any delays, valuation disappointment at IPO, or post‑spin margin issues could pressure MDT’s stock in the near term. [73] - Intense Competition in Key Markets
- Robotics: Hugo goes up against Intuitive Surgical’s deeply entrenched da Vinci platform.
- Diabetes: The Diabetes business competes with Dexcom, Abbott, Tandem and others in an innovation‑heavy space.
- Cardiology and neuromodulation: Large peers (Boston Scientific, Abbott, etc.) vying for share across many categories. [74]
- Regulatory and Reimbursement Uncertainty
While recent decisions (CMS RDN coverage, device approvals) have been favourable, Medtronic remains exposed to ongoing regulatory scrutiny, pricing pressure and policy shifts across its global footprint, especially in the U.S. and Europe. [75]
FAQs: Medtronic (MDT) Stock on 6 December 2025
Is Medtronic (MDT) a buy, sell or hold right now?
- Consensus: Most platforms rate MDT a Buy or Moderate Buy, with mid‑single‑digit to high‑single‑digit projected EPS growth and roughly 7–9% price upside based on average 12‑month target prices. [76]
- Dissenting view: Some analysts (e.g., Wall Street Zen) have shifted to Hold, citing the stock’s strong run in 2025, tariff headwinds and spin‑off risk. [77]
Whether MDT is suitable for you depends on your risk tolerance, time horizon and portfolio mix. This article is for information only and is not personalized investment advice.
What is the current Medtronic dividend, and how safe is it?
- Quarterly dividend: $0.71 per share, payable 16 January 2026 to shareholders of record on 26 December 2025. [78]
- Yield: Around 2.8% at recent prices. [79]
- Track record: 48 years of consecutive dividend increases and inclusion in the Dividend Aristocrats index. [80]
Analysts generally view the dividend as well‑covered by earnings and cash flow under current guidance.
What are the top growth drivers for Medtronic heading into 2026?
Based on the latest news and management commentary, the most important growth levers appear to be:
- Pulsed Field Ablation (PFA) for atrial fibrillation via the Affera/Sphere‑9 platform. [81]
- Symplicity Spyral RDN backed by the new CMS NCD. [82]
- Hugo robotic surgery expansion beyond urology. [83]
- MiniMed 780G + Instinct sensor and Medtronic’s broader CGM ecosystem, both inside and eventually outside the company after the spin‑off. [84]
Bottom Line: How Medtronic Stock Looks on 6 December 2025
As of 6 December 2025, Medtronic sits at an interesting inflection point:
- Fundamentals are improving, with stronger growth, raised guidance and multiple product launches across robotics, diabetes and hypertension. [85]
- The dividend remains a core attraction, supported by nearly five decades of increases and a competitive yield. [86]
- Valuation is no longer cheap but appears reasonable against medtech peers, especially given the potential upside from new platforms and the diabetes spin‑off. [87]
- Risks – especially tariffs, competition and execution on the MiniMed separation – are significant and bear watching. [88]
For long‑term investors who want exposure to global medtech innovation plus a reliable and growing dividend, Medtronic is increasingly being framed as a blue‑chip compounder rather than a hyper‑growth stock. For more aggressive traders, near‑term returns may depend on how quickly Hugo adoption, renal denervation uptake and diabetes spin‑off details translate into visible earnings acceleration.
As always, consider your own financial situation and consult a qualified professional before making investment decisions.
References
1. www.marketbeat.com, 2. www.marketbeat.com, 3. www.marketbeat.com, 4. www.marketbeat.com, 5. www.marketbeat.com, 6. www.marketbeat.com, 7. nai500.com, 8. www.marketbeat.com, 9. www.marketbeat.com, 10. stockanalysis.com, 11. www.marketbeat.com, 12. www.marketbeat.com, 13. www.marketbeat.com, 14. www.marketbeat.com, 15. www.marketbeat.com, 16. news.medtronic.com, 17. news.medtronic.com, 18. www.marketbeat.com, 19. news.medtronic.com, 20. news.medtronic.com, 21. finviz.com, 22. www.stocktitan.net, 23. www.stocktitan.net, 24. www.stocktitan.net, 25. www.stocktitan.net, 26. www.stocktitan.net, 27. finviz.com, 28. www.prnewswire.com, 29. www.prnewswire.com, 30. www.prnewswire.com, 31. www.marketscreener.com, 32. finviz.com, 33. news.medtronic.com, 34. news.medtronic.com, 35. evtoday.com, 36. investingnews.com, 37. news.medtronic.com, 38. news.medtronic.com, 39. news.medtronic.com, 40. news.medtronic.com, 41. news.medtronic.com, 42. news.medtronic.com, 43. news.medtronic.com, 44. news.medtronic.com, 45. news.medtronic.com, 46. news.medtronic.com, 47. news.medtronic.com, 48. news.medtronic.com, 49. news.medtronic.com, 50. nai500.com, 51. news.medtronic.com, 52. idataresearch.com, 53. www.fiercebiotech.com, 54. news.medtronic.com, 55. www.medtechdive.com, 56. www.medicaldesignandoutsourcing.com, 57. www.marketbeat.com, 58. stockanalysis.com, 59. stockanalysis.com, 60. stockanalysis.com, 61. stockanalysis.com, 62. www.marketbeat.com, 63. www.nasdaq.com, 64. www.nasdaq.com, 65. stockanalysis.com, 66. news.medtronic.com, 67. nai500.com, 68. www.stocktitan.net, 69. news.medtronic.com, 70. news.medtronic.com, 71. news.medtronic.com, 72. www.barrons.com, 73. www.fiercebiotech.com, 74. finviz.com, 75. news.medtronic.com, 76. www.marketbeat.com, 77. www.marketbeat.com, 78. news.medtronic.com, 79. www.marketbeat.com, 80. news.medtronic.com, 81. news.medtronic.com, 82. investingnews.com, 83. www.stocktitan.net, 84. www.prnewswire.com, 85. news.medtronic.com, 86. news.medtronic.com, 87. www.nasdaq.com, 88. www.barrons.com
